

Takao Kamai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5787301/publications.pdf>

Version: 2024-02-01

78
papers

1,532
citations

471061

17
h-index

329751

37
g-index

86
all docs

86
docs citations

86
times ranked

2551
citing authors

#	ARTICLE	IF	CITATIONS
1	Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. <i>Clinical Cancer Research</i> , 2003, 9, 2632-41.	3.2	294
2	Overexpression of RhoA, Rac1, and Cdc42 GTPases Is Associated with Progression in Testicular Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4799-4805.	3.2	227
3	Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. <i>BMC Cancer</i> , 2010, 10, 164.	1.1	72
4	High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2008, 122, 2391-2397.	2.3	67
5	Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 509.	1.1	60
6	Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. <i>BMC Cancer</i> , 2009, 9, 270.	1.1	55
7	Recent advances in the treatment of metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2013, 20, 944-955.	0.5	54
8	Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. <i>Cancer Medicine</i> , 2016, 5, 1810-1820.	1.3	46
9	The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. <i>BMC Cancer</i> , 2014, 14, 412.	1.1	33
10	Update on advances in molecular PET in urological oncology. <i>Japanese Journal of Radiology</i> , 2016, 34, 470-485.	1.0	31
11	Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer. <i>BMC Cancer</i> , 2015, 15, 1097.	1.1	30
12	STAT3 Polymorphism Can Predict the Response to Interferon- β Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 745-752.	0.9	28
13	Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. <i>Biomedical Research</i> , 2008, 29, 155-161.	0.3	27
14	Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2009-2021.	2.0	27
15	Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy. <i>BMC Cancer</i> , 2017, 17, 372.	1.1	21
16	Clinical Significance of Serum Soluble T Cell Regulatory Molecules in Clear Cell Renal Cell Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	20
17	Increased alpha-taxilin protein expression is associated with the metastatic and invasive potential of renal cell cancer. <i>Biomedical Research</i> , 2011, 32, 103-110.	0.3	19
18	Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis. <i>BMC Cancer</i> , 2007, 7, 159.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer. <i>BMC Cancer</i> , 2019, 19, 1137.	1.1	17
20	Detection of Muscle-Invasive Bladder Cancer on Biparametric MRI Using Vesical Imaging-Reporting and Data System and Apparent Diffusion Coefficient Values (VI-RADS/ADC). <i>Bladder Cancer</i> , 2020, 6, 161-169.	0.2	17
21	Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma?. <i>Biomedical Research</i> , 2009, 30, 171-176.	0.3	16
22	Expression of RhoA mRNA and activated RhoA in urothelium and smooth muscle, and effects of a rho-kinase inhibitor on contraction of the porcine urinary bladder. <i>Neurourology and Urodynamics</i> , 2009, 28, 521-528.	0.8	16
23	Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 793-808.	2.0	16
24	Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 689-702.	2.0	16
25	Immunohistochemical expression of sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 169-178.	0.7	15
26	The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia. <i>Journal of Pharmacological Sciences</i> , 2015, 128, 65-70.	1.1	14
27	Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report. <i>BMC Cancer</i> , 2016, 16, 232.	1.1	14
28	Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. <i>European Journal of Endocrinology</i> , 2020, 183, K7-K12.	1.9	13
29	Metronomic Oral Cyclophosphamide Chemotherapy Possibly Contributes to Stabilization of Disease in Patients With Metastatic Castration-Resistant Prostate Cancer: A Prospective Analysis of Consecutive Cases. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e197-e203.	0.9	12
30	Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer. <i>Open Heart</i> , 2018, 5, e000666.	0.9	12
31	Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold. <i>International Journal of Clinical Oncology</i> , 2020, 25, 472-478.	1.0	12
32	Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?. <i>International Journal of Urology</i> , 2015, 22, 1143-1148.	0.5	11
33	Increased Nrf2 expression by renal cell carcinoma is associated with postoperative chronic kidney disease and an unfavorable prognosis. <i>Oncotarget</i> , 2018, 9, 28351-28363.	0.8	10
34	Sex steroid hormone receptors in bladder cancer: Usefulness in differential diagnosis and implications in histogenesis of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 353.e9-353.e15.	0.8	10
35	A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy. <i>Journal of Kidney Cancer and VHL</i> , 2020, 7, 6-10.	0.2	10
36	Protein Profiling of Blood Samples from Patients with Hereditary Leiomyomatosis and Renal Cell Cancer by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. <i>International Journal of Molecular Sciences</i> , 2012, 13, 14518-14532.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β_3 -Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 158-166.	0.6	9
38	Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy. International Journal of Clinical Oncology, 2018, 23, 338-346.	1.0	9
39	Single minimum incision endoscopic radical nephrectomy for renal tumors with preoperative virtual navigation using 3D-CT volume-rendering. BMC Urology, 2010, 10, 7.	0.6	8
40	Prognosis of metastatic renal cell carcinoma with first-line interferon- α therapy in the era of molecular-targeted therapy. Cancer Science, 2016, 107, 1013-1017.	1.7	8
41	Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α_1 -Blockers. International Neurourology Journal, 2017, 21, 197-203.	0.5	8
42	Significant association of interleukin 10 receptor mRNA levels with renal cell carcinoma metastasis. Biomedical Research, 2008, 29, 19-25.	0.3	7
43	Effects of fasudil, a Rho-kinase inhibitor, on contraction of pig bladder tissues with or without urothelium. International Journal of Urology, 2009, 16, 959-966.	0.5	7
44	A Rare Complication of Chylous Leakage After Open Partial Nephrectomy Successfully Resolved by Somatostatin Analogue. Urology Case Reports, 2015, 3, 195-197.	0.1	7
45	Single nucleotide variants of succinate dehydrogenase A gene in renal cell carcinoma. Cancer Science, 2021, 112, 3375-3387.	1.7	7
46	Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 565-578.	2.0	7
47	Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report. OncoTargets and Therapy, 2014, 7, 289.	1.0	6
48	Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy. BMC Urology, 2017, 17, 47.	0.6	6
49	5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase. Oncology Letters, 2019, 17, 4429-4436.	0.8	6
50	Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer. BMC Cancer, 2018, 18, 493.	1.1	5
51	Comparative accuracy of the Liliu \pm 200 portable ultrasound bladder scanner and conventional transabdominal ultrasonography for postvoid residual urine volume measurement in association with the clinical factors involved in measurement errors. Neurourology and Urodynamics, 2021, 40, 183-192.	0.8	5
52	Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear-cell renal cell carcinoma. IJU Case Reports, 2021, 4, 95-99.	0.1	5
53	Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy. International Journal of Clinical Oncology, 2017, 22, 174-180.	1.0	4
54	The Predictive Value of Glycated Hemoglobin and Albumin for the Clinical Course Following Hospitalization of Patients with Febrile Urinary Tract Infection. Infection and Chemotherapy, 2018, 50, 228.	1.0	4

#	ARTICLE	IF	CITATIONS
55	Feeling of incomplete emptying with little postvoid residual in patients with lower urinary tract symptoms: Clinical implications and treatment outcomes. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O59-O64.	0.6	4
56	Ambulatory Urodynamics in Asymptomatic, Young, Healthy Male Volunteers. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 29-34.	0.6	3
57	Case of hydrocele testis caused by vaginalitis, a rare manifestation of immunoglobulin G4-related disease. International Journal of Urology, 2017, 24, 771-773.	0.5	3
58	Immune-related myositis resulting from combination therapy of ipilimumab and nivolumab in patient with metastatic renal cell carcinoma. BMJ Case Reports, 2020, 13, e235199.	0.2	3
59	Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation. BMC Cancer, 2022, 22, 289.	1.1	3
60	Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. Scientific Reports, 2022, 12, .	1.6	3
61	Oncocytic Carcinoid of the Kidney Positively Detected by I-131 MIBG Scintigraphy. Clinical Nuclear Medicine, 2011, 36, 1025-1028.	0.7	2
62	Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder. LUTS: Lower Urinary Tract Symptoms, 2013, 5, 11-16.	0.6	2
63	Abnormal 18F-FDG uptakes in the prostate due to two different conditions of urine reflux: a mimicker of prostate cancer. SpringerPlus, 2016, 5, 46.	1.2	2
64	Case of prostate stromal tumour of uncertain malignant potential where positron emission tomography with 18F-fluorodeoxyglucose was useful for surgical planning. BMJ Case Reports, 2020, 13, e235738.	0.2	2
65	Plasmacytoid urothelial carcinoma of renal pelvis with positive zinc finger E-box-binding homeobox 1: a case report. Diagnostic Pathology, 2020, 15, 124.	0.9	2
66	A case of penile self-mutilation during a suicidal attempt successfully treated using a multidisciplinary approach. IJU Case Reports, 2022, 5, 165-167.	0.1	2
67	Extravasation of Urine Associated with Bilateral Complete Ureteral Duplication, Vesicoureteral Reflux and Benign Prostatic Hyperplasia. Urology Case Reports, 2017, 11, 47-49.	0.1	1
68	Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases. Oncology and Therapy, 2018, 6, 157-171.	1.0	1
69	Clinical Significance of 18F-fluorodeoxyglucose and Glucose Transporter 1 mRNA in Clear Cell Renal Cell Carcinoma. Anticancer Research, 2021, 41, 5179-5188.	0.5	1
70	Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma. Oncotarget, 2018, 9, 4188-4199.	0.8	1
71	Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma. Cancer Science, 2022, , .	1.7	1
72	Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma. IJU Case Reports, 2022, 5, 293-296.	0.1	1

#	ARTICLE	IF	CITATIONS
73	A case of giant hemorrhagic hydrocele testis. Urology Case Reports, 2018, 18, 44-45.	0.1	0
74	Use of STAT3 polymorphisms to predict overall survival in patients treated with interferon-alpha for metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e15048-e15048.	0.8	0
75	Importance of performance status, corrected calcium, and microvascular invasion in predicting overall survival in patients with metastatic renal cell carcinoma at the era of molecular targeted therapy.. Journal of Clinical Oncology, 2013, 31, e15588-e15588.	0.8	0
76	Carbon dioxide insufflation to control intractable bleeding during transurethral resection of bladder tumor. Indian Journal of Urology, 2019, 35, 73-74.	0.2	0
77	Epidemiological estimates and early detection of polycystic kidney disease by ultrasonographic assessment in Japan. Medical Ultrasonography, 2021, , .	0.4	0
78	A case of renal trauma successfully treated by close monitoring of intravesical pressure and subsequent intervention. Urology Case Reports, 2022, 42, 102014.	0.1	0